CD33-blocking antibody, CD33-blocking humanized antibody and use thereof

By humanizing CD33 antibodies HZAB_1 and HZAB_2, the problems of insignificant efficacy and safety of existing drugs in the treatment of small cell lung cancer, colorectal neuroendocrine carcinoma and liver metastasis of neuroendocrine tumors have been solved. High specificity of CD33 blocking has been achieved, which significantly inhibits tumor growth and liver metastasis.

WO2026119012A1 Publication Date: 2026-06-11RENJI HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
RENJI HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
Filing Date
2025-11-28
Publication Date
2026-06-11

AI Technical Summary

⚠Technical Problem

Existing CD33 antibody drugs have not shown significant efficacy in treating small cell lung cancer and colorectal neuroendocrine carcinoma, and there are safety concerns. Treatment of liver metastases from neuroendocrine tumors is difficult, targeted drugs and chemotherapy have limited efficacy, and immunotherapy has poor results.

⚗Method used

We developed CD33 blocking antibodies HZAB_1 and HZAB_2, and improved the specificity and affinity of rabbit monoclonal antibodies for CD33 through humanization, so as to prepare drugs for the treatment of small cell lung cancer, colorectal neuroendocrine carcinoma and liver metastases of neuroendocrine tumors.

🎯Benefits of technology

It improves the phagocytic efficiency of macrophages on tumor cells, significantly slows tumor progression, inhibits liver metastasis, and provides a safe and effective treatment option.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
Patent Text Reader

Abstract

Provided are a CD33-blocking antibody, a CD33-blocking humanized antibody and the use thereof. The CD33-blocking antibody is HZAB_1 or HZAB_2. The HZAB_2 comprises a heavy chain variable region having an amino acid sequence as set forth in SEQ ID NO. 3 and a light chain variable region having an amino acid sequence as set forth in SEQ ID NO. 4. The HZAB_1 and HZAB_2 antibodies can enhance the phagocytic efficiency of macrophages against colorectal neuroendocrine carcinoma cells and small cell lung cancer cells, thereby delaying the progression of colorectal neuroendocrine carcinoma and small cell lung cancer. Also provided is a CD33-blocking humanized antibody obtained by performing humanization on the HZAB_2 antibody. The CD33-blocking humanized antibody comprises a heavy chain variable region having an amino acid sequence as set forth in SEQ ID NO. 30 and a light chain variable region having an amino acid sequence as set forth in SEQ ID NO. 31. The humanized CD33-blocking antibody can inhibit liver metastasis of neuroendocrine prostate cancer and liver metastasis of small cell lung cancer.
Need to check novelty before this filing date? Find Prior Art